У нас вы можете посмотреть бесплатно Melanoma in Minutes: Evidence-Driven Care for Improved Patient Outcomes – Module 2 или скачать в максимальном доступном качестве, видео которое было загружено на ютуб. Для загрузки выберите вариант из формы ниже:
Если кнопки скачивания не
загрузились
НАЖМИТЕ ЗДЕСЬ или обновите страницу
Если возникают проблемы со скачиванием видео, пожалуйста напишите в поддержку по адресу внизу
страницы.
Спасибо за использование сервиса ClipSaver.ru
Click here to claim your CME/NCPD credit: https://bit.ly/43cnjNN Click here to go back and listen to module 1 of this podcast series: • Melanoma in Minutes: Evidence-Driven Care ... In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments. Follow us here: Facebook / i3health Instagram / i3health Linkedin / i3health Soundcloud / i3-health X / i3health STATEMENT OF NEED Melanoma is a complex disease which has seen remarkable progress in recent years due to the introduction of immunotherapy and targeted therapies. While emerging treatments have prolonged survival and improved outcomes, they can be associated with significant toxicities that impact organ systems throughout the body (Brahmer et al, 2021; Boutros et al, 2024). In order to maximize the efficacy of novel therapies, it is vital for members of the care team to remain up to date on the management of immune-related adverse events, employ interdisciplinary supportive care strategies, and provide clear and effective education to their patients. In Module 2 of this podcast, Michael A. Davies, MD, PhD, Professor and Chairman of the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, will explore strategies for enhancing patient care and keeping pace with advancements in melanoma. DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES i3 Health endorses the standards of the ACCME and ANCC that require everyone in a position to control the content of a CME/NCPD activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD activity. CME/NCPD activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession. A conflict of interest is created when an individual has an opportunity to affect CME/NCPD content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits. i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services. Relevant financial relationships exist between the following individuals and ineligible companies: The i3 Health planners, reviewers, and managers have nothing to disclose. Michael A. Davies, MD, PhD, discloses that he has served on an advisory board or panel for ABM, Apexigen, Bristol Myers Squibb, Eisai, Iovance, Novartis, Nurix, Pfizer, Replimune, and Roche; and that he has received grants/research support from ABM, Lead Pharma, and Pfizer. i3 Health has mitigated all relevant financial relationships. #MelanomaCare #Immunotherapy #TargetedTherapies #CancerCare #OncologyEducation #MelanomaResearch #PersonalizedMedicine #Biomarkers #OncologyInnovation #PatientOutcomes